Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Michael A Davies
Affiliation
The University of Texas MD Anderson Cancer Center
ORCID
Career Start Year
1997
Papers
289
H Index
81
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
37622466
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.
Pigment Cell Melanoma Res
2024
37622466
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.
Pigment Cell Melanoma Res
2024
36054930
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
Neuro Oncol
2023
36166093
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
Clin Cancer Res
2023
36054930
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
Neuro Oncol
2023
37647056
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.
JAMA Dermatol
2023
37414216
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Ann Oncol
2023
37093838
Diversity, equity, and inclusion in the melanoma research community.
Pigment Cell Melanoma Res
2023
37285560
Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer.
JCO Precis Oncol
2023
37213225
Loss of AMPKα2 promotes melanoma tumor growth and brain metastasis.
iScience
2023
36711814
Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.
bioRxiv
2023
36510640
Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.
Neuro Oncol
2023
36894629
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature
2023
36871660
Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.
J Invest Dermatol
2023
36627494
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature
2023
37444561
Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.
Cancers (Basel)
2023
36477181
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Clin Cancer Res
2023
36997799
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Nat Med
2023
37503252
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade.
Res Sq
2023
37503252
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade.
Res Sq
2023
37647056
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.
JAMA Dermatol
2023
37285560
Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer.
JCO Precis Oncol
2023
37213225
Loss of AMPKα2 promotes melanoma tumor growth and brain metastasis.
iScience
2023
37414216
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Ann Oncol
2023
37444561
Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.
Cancers (Basel)
2023
36997799
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Nat Med
2023
37093838
Diversity, equity, and inclusion in the melanoma research community.
Pigment Cell Melanoma Res
2023
36477181
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Clin Cancer Res
2023
36871660
Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.
J Invest Dermatol
2023
36711814
Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.
bioRxiv
2023
36510640
Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.
Neuro Oncol
2023
36894629
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature
2023
36627494
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature
2023
36166093
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
Clin Cancer Res
2023
34152638
Re-thinking therapeutic development for CNS metastatic disease.
Exp Dermatol
2022
35912544
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
Pigment Cell Melanoma Res
2022
35706413
Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
Cancer Immunol Res
2022
35705814
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature
2022
35762249
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
Neuro Oncol
2022
36289334
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Nature
2022
35810190
Multi-modal molecular programs regulate melanoma cell state.
Nat Commun
2022
35803246
Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
Cell
2022
35552271
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.
J Clin Invest
2022
35413951
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Nat Commun
2022
36324592
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
Front Oncol
2022
35537412
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Cancer Cell
2022
35977349
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
JCO Precis Oncol
2022
36518525
Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors.
NAR Cancer
2022
34152638
Re-thinking therapeutic development for CNS metastatic disease.
Exp Dermatol
2022
35278716
Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020.
Pract Radiat Oncol
2022
1 - 50 of 578
Column Actions
Search
Recommended Authors
Katie M Campbell
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year
2014
Number of shared co-authors
6
Malaka Ameratunga
Australia Central Clinical School, Monash University
Career Start Year
2014
Number of shared co-authors
0
Brian J Capaldo
Center for Cancer Research, National Cancer Institute
Career Start Year
2012
Number of shared co-authors
1
Gareth Rivalland
Auckland City Hospital
Career Start Year
2010
Number of shared co-authors
0
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year
2009
Number of shared co-authors
37
Maxim Sidorov
California Pacific Medical Center Research Institute
Career Start Year
2009
Number of shared co-authors
0
Jesse M Zaretsky
University of California los angeles
Career Start Year
2007
Number of shared co-authors
8
Heidi V N K??sters-Vandevelde
Canisius Wilhelmina Hospital
Career Start Year
2006
Number of shared co-authors
0
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year
2006
Number of shared co-authors
10
Alan H Bryce
Mayo Clinic
Career Start Year
2006
Number of shared co-authors
3
Joshua C Anderson
University of Alabama at Birmingham
Career Start Year
2005
Number of shared co-authors
1
Christine A Pratilas
Johns Hopkins University School of Medicine
Career Start Year
2004
Number of shared co-authors
9
Matthias Preusser
Medical University of Vienna
Career Start Year
2003
Number of shared co-authors
10
Daniel Zingg
Netherlands Cancer Institute
Career Start Year
2001
Number of shared co-authors
5
Daniela Mihic-Probst
University Hospital Zurich
Career Start Year
2001
Number of shared co-authors
8
Christopher D Willey
University of Alabama at Birmingham
Career Start Year
2000
Number of shared co-authors
1
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year
1999
Number of shared co-authors
9
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Career Start Year
1999
Number of shared co-authors
10
David J Liewehr
Center for Cancer Research
Career Start Year
1999
Number of shared co-authors
3
Travis J Hollmann
Memorial Sloan Kettering Cancer Center
Career Start Year
1998
Number of shared co-authors
9
Cindy Sander
UPMC Hillman Cancer Center
Career Start Year
1997
Number of shared co-authors
12
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year
1997
Number of shared co-authors
7
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year
1996
Number of shared co-authors
11
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year
1995
Number of shared co-authors
15
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year
1994
Number of shared co-authors
1
Timothy A Chan
Cleveland Clinic.
Career Start Year
1994
Number of shared co-authors
39
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year
1993
Number of shared co-authors
6
Rene Gonzalez
University of Colorado Anschutz Medical Campus
Career Start Year
1990
Number of shared co-authors
24
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year
1990
Number of shared co-authors
8
Emile E Voest
The Netherlands Cancer Institute
Career Start Year
1989
Number of shared co-authors
3
row(s) 1 - 30 of 30
Collaborators
Jeffrey E Gershenwald
The University of Texas MD Anderson Cancer Center
Co-authored papers
62
Jennifer A Wargo
Co-authored papers
58
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers
54
Hussein A Tawbi
MD Anderson Cancer Center
Co-authored papers
50
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers
34
Georgina V Long
Co-authored papers
31
Andrew E Aplin
Thomas Jefferson University
Co-authored papers
19
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Co-authored papers
17
Guo Chen
China Pharmaceutical University
Co-authored papers
16
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers
15
Dirk Schadendorf
Co-authored papers
14
Yiling Lu
Co-authored papers
14
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Co-authored papers
13
Richard A Scolyer
Co-authored papers
11
Antoni Ribas
University of California Los Angeles (university of california los angeles)
Co-authored papers
11
Katherine Stemke-Hale
MD Anderson Cancer Center, University of Texas
Co-authored papers
11
Caroline Robert
Co-authored papers
10
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers
10
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers
10
Mark J Routbort
University of Texas MD Anderson Cancer Center
Co-authored papers
10
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers
10
Dave S B Hoon
Saint John's Cancer Institute at Saint John's Health Center
Co-authored papers
9
Linghua Wang
The University of Texas M. D. Anderson
Co-authored papers
9
Reinhard Dummer
University Hospital Zurich
Co-authored papers
8
Jianhua Hu
Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences
Co-authored papers
8
Janice N Cormier
Co-authored papers
8
Priscilla K Brastianos
Co-authored papers
8
Marcus Bosenberg
Yale School of Medicine
Co-authored papers
8
Yardena Samuels
Weizmann Institute of Science
Co-authored papers
8
Sherise D Ferguson
The University of Texas MD Anderson Cancer Center
Co-authored papers
8
1 - 30